Oruba Presents State-of-the-Art Self-Operating Uroflowmeters
|
By LabMedica International staff writers Posted on 15 Nov 2023 |

Oruba Technology & Innovation (Langenfeld, Germany) is demonstrating its state-of-the-art self-operating uroflowmeters at MEDICA 2023.
Oruba is showcasing Oruflow, the world’s first self-operating uroflowmeter. As a point-of-care diagnostic device, it eases and accelerates the uroflowmetry process in a hygienic and comfortable atmosphere. The self-cleaning and hygienic point-of-care solution has revolutionized the process of uroflowmetry, making it a crucial part of every hospital and urology clinic. The self-operating uroflowmeter can be operated in easy steps. The patient first has to scan the hospital barcode to start the examination. The on-board screen helps the patients and guides them during the examination. Oruba Oruflow measures the test parameters and prepares the report. The patient then uses the hospital barcode to let Oruba Oruflow save the examination report into the hospital information system automatically. The patient can receive the results of the examination in seconds without any operator guidance.
As soon as the urination finishes, Oruba Oruflow prints the results out and cleans itself automatically. The patient can go to the doctor directly and the device gets ready for the next examination in one minute. Oruba Oruflow does not require an operator or nurse guidance and the patient does the test in an actual restroom comfort. Oruba Oruflow technology creates a hygienic and relaxed clinical atmosphere and prevents the unpleasant smell and dirt problem. Oruba Oruflow’s high-developed IoT technology and auto-notification system allows it to provide online technical service and solve the problem in minutes. The yearly maintenance and software upgrades are done from the Oruba HQ
Related Links:
Oruba Technology & Innovation
Latest Medica 2023 News
- Absology Showcases Latest Advancements in Medical Diagnostics
- Noul Showcases AI-Driven Blood and Cancer Diagnostic Platform
- Awareness Technology Exhibits Incredibly Flexible ChemWell 2 ELISA and Chemiluminescent Analyzer
- BioVendor Group Demonstrates Unique IVD Platform and Immunoblot Test
- Greiner Bio-One Highlights Magnetic 3D Cell Culture Technology
- Fujirebio Showcases Range of Novel Testing Solutions
- Sentinel Diagnostics Demonstrates New SENTiNAT 200 and STAT-NAT Kits for Infectious Diseases
- DiaSys Showcases High Quality Diagnostic Reagents and System Solutions
- Randox Exhibits Full Range of Molecular Diagnostic Solutions
- Alcor Scientific Demonstrates Fully-Automated ESR Analyzers
- Bosch Healthcare Presents Vivalytic Point-of-Care PCR System
- CerTest Presents Innovations Related to VIASURE Products
- Vircell Highlights All-in-One CLIA System and Real Time PCR Kits
- Tianlong Showcases Cutting-Edge Products and Innovative Molecular Diagnostic Solutions
- Getein Biotech Exhibits Advanced POCT Analyzers
- LumiraDx Demonstrates Transformative Tests and Technologies
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
Lynch syndrome is a hereditary condition that increases risk for colorectal and endometrial cancers and often results in earlier-onset disease. Clinicians need better ways to stratify asymptomatic carriers... Read more
Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive condition characterized by obstructed pulmonary blood flow and strain on the right heart, with half of patients dying within five years of diagnosis.... Read more
Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
Racial survival disparities in early-stage breast cancer remain a persistent clinical concern in the United States, with Black women experiencing higher mortality despite similar treatments.... Read more
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more








